Multidimensional Burden of Platinum Resistant Ovarian Cancer (PROC) on Patients and Caregivers in Canada

NCT07035067 | Enrolling By Invitation

• 1 other identifier: Ovarian Cancer
• Study Type: observational
• Target: 150
• Locations: 1 country
• Sites: 1

Brief Summary

Filling the gap in Canadian evidence on the burden of PROC on QoL is essential. It will help better understand the impact of PROC on multiple aspects of the lives of patients and their caregivers and the real-life hurdles faced by PROC patients and their caregivers. The outputs of this study will help better understand the hurdles and challenges they face and the significant unmet medical need.

Conditions

Ovarian Cancer; Caregiver Burden; Patient Burden

Outcome Measures

Primary Outcomes (1)

• To estimate the quality of life of patient with ovarian cancer

  Using the the Functional Assessment of Cancer Therapy - Ovarian (FACT-O) and EuroQol 5-dimendion 5-level (EQ-5D-5L)

  At recruitment

Secondary Outcomes (4)

• Patient's symptoms assessment

  At recruitment

• Caregiver's Quality of Life

  At recruitment

• Patients and caregivers work productivity loss and activity impairment

  At recruitment

• Patient's preference in treatment

  At recruitment

Study Arms (2)

Patients with PROC part of Ovarian Cancer Canada mailing lists

Other: No intervention

Caregiver of PROC patients part of Ovarian Cancer Canada mailing lists

Other: No intervention

Interventions

No intervention OTHER

No specific intervention is assess in this study.

Caregiver of PROC patients part of Ovarian Cancer Canada mailing lists; Patients with PROC part of Ovarian Cancer Canada mailing lists

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with ovarian cancer and caregivers of patients with ovarian cancer who are part Ovarian Cancer Canada mailing list.

You may qualify if:

• ≥18 years old
• Patients with PROC who received \>1 prior line of therapy identified through a screening survey. PROC will be defined as recurrence less than 6 months after last platinum chemotherapy (i.e. carboplatin or cisplatin)
• Ability to read and understand French or English
• Signature of ICF

You may not qualify if:

• Patients with PSOC, defined as those who:
• Have not progressed within less than 6 months after completion of platinum-based chemotherapy or;
• Are still on platinum chemotherapy or;
• Receive maintenance therapy.
• Patients with platinum-refractory ovarian cancer, defined as not responding or disease progressing during therapy or within three months after the last dose
• ≥18 years old
• Current caregiver of a patient with PROC (see definition to be used above) who received \>1 prior line of therapy identified through a screening survey.
• Ability to read and understand French or English
• Signature of ICF.
• Caregivers of patients with PSOC (see definition above)
• Caregivers of PROC patients who have passed away
• Caregivers of platinum-refractory patients (see definition above)

Sponsors & Collaborators

• PeriPharm: lead

Study Sites (1)

PROxy Network, an initiative of PeriPharm Inc.

Montreal, Quebec, H2Y 1V3, Canada

Location

MeSH Terms

Conditions

Ovarian Neoplasms; Caregiver Burden

Condition Hierarchy (Ancestors)

Endocrine Gland Neoplasms; Neoplasms by Site; Neoplasms; Ovarian Diseases; Adnexal Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Neoplasms, Female; Urogenital Neoplasms; Genital Diseases; Endocrine System Diseases; Gonadal Disorders; Stress, Psychological; Behavioral Symptoms; Behavior

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 4, 2025
• First Posted: June 24, 2025
• Study Start: July 15, 2025
• Primary Completion: May 1, 2026
• Study Completion (Estimated): June 1, 2026
• Last Updated: December 23, 2025

Record last verified: 2025-12

Data Sharing

• IPD Sharing: Will not share

Locations

CA (1)